Previously, we studied patients with metastatic melanoma and mRCC treated with HD-IL2 and undertook sequential immune monitoring using flow cytometry, which revealed changes in immune profiles that were related to IL2 response (16). This evidence concerns the gene IL2 and metastatic melanoma.